Fosrenol Shire Pharmaceuticals Group plc - Treatment for Hyperphosphataemia in ESRD Patients
Fosrenol is a non-calcium, non-aluminum phosphate binder formulated as an easy to use, chewable only tablet that can be taken without water. Fosrenol is used to reduce high phosphorus levels in end-stage renal disease (ESRD) patients.Posted: October 2004
Related articles
- Fosrenol: FDA Action Date Extended, US Launch Target Unaffected - July 20, 2004
Fosrenol (lanthanum carbonate) FDA Approval History
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.
